Related Experiment Video
Updated: Apr 7, 2026

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
Published on: October 27, 2014
Rituximab for sight-threatening refractory pediatric Vogt-Koyanagi-Harada disease
Raid M R Umran1, Zaid Y H Shukur2
1a Department of Pediatrics , University of Kufa, College of Medicine, Al- Zahraa Teaching Hospital , Najaf , Iraq.
Abstract:
Rituximab was trialed in a refractory Vogt-Koyanagi-Harada disease (VKH). A 10-year-old girl with panuveitis recalcitrant to treatment, including corticosteroids, was diagnosed with VKH 20 months later. Following rituximab at 0, 1, 6, and 18 months, response was favorable after the second dose, usual life activity resumed after the third dose (uveitis was inactivated and vision improved), and eyes stabilized 9 months after the fourth dose. Rituximab is effective in the treatment and long-term control of advanced, pediatric VKH.
Related Concept Videos
Treatment Resistent Cancers
Treatment Resistant Cancers
Open Angle Glaucoma: Treatment
Drugs such as carbonic anhydrase inhibitors, α2- and...
Tumor Immunotherapy
Angle Closure Glaucoma: Treatment
![Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F62334.jpg&w=3840&q=50)
